Kalbe Farma Sets Up R&D Base in Singapore to Focus on Drug Development of Biopharmaceuticals

29-May-2006

Indonesian-listed pharmaceutical company, PT Kalbe Farma Tbk. (Kalbe Farma) officially opened its office for research coordination and licensing in Singapore. The company focuses on research and development of biopharmaceuticals and other innovative products as well as diagnostic tools. Known as Innogene Kalbiotech Pte Ltd (Innogene), it is a wholly owned subsidiary of Kalbe. Innogene aims to specialise in oncology, intensive care, therapeutic and preventive vaccines.

To advance its vision to become a leading biopharmaceutical company, Innogene also collaborates with other local and international companies, researchers and institutions to acquire, develop and patent innovative pharmaceuticals and diagnostic products for the global market. They include Fraunhofer-Gessellschaft, Europe's largest applied science organisation to develop affordable diagnostic kits for Hepatitis C, Canada's YM BioSciences Inc to develop nimotuzumab also known as hR3 for treating brain tumour and Recombio, a Swiss company to develop a cancer vaccine, IE10, for the treatment of non small cell lung carcinoma and breast cancer. Innogene is also working with Singapore's Lynk Biotechnologies to develop and license out innovative products for application in different therapeutic classes.

Other news from the department business & finance

More news from our other portals

So close that even
molecules turn red...